# Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma

> **NCT05547828** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Xinxiang Medical College** · enrollment: 20 (estimated)

## Conditions studied

- ESCC

## Interventions

- **DRUG:** Tislelizumab combined with chemoradiotherapy

## Key facts

- **NCT ID:** NCT05547828
- **Lead sponsor:** The First Affiliated Hospital of Xinxiang Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-20
- **Primary completion:** 2024-12-20
- **Final completion:** 2024-12-20
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05547828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05547828, "Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05547828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*